Acumen Pharmaceuticals (ABOS) grants RSUs and options to CRO

Rhea-AI Filing Summary

Acumen Pharmaceuticals Chief Regulatory Officer Amy Schacterle reported new equity awards. On January 16, 2026, she received 84,600 shares of Common Stock as a restricted stock unit award at a reported price of $0 per share, bringing her directly held Common Stock to 92,303 shares. The RSUs vest in three equal annual installments starting one year after the grant date, as long as she remains in continuous service.

She was also granted an employee stock option for 126,900 shares of Common Stock with an exercise price of $1.89 per share. This option vests in 48 equal monthly installments so that it is fully vested on the fourth anniversary of the grant date, subject to her continued service, and she held 126,900 options following the transaction.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Schacterle Amy

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	126,900	$0.00	--
Grant/Award	Common Stock	84,600	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 126,900 shares (Direct); Common Stock — 92,303 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schacterle Amy

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MA 02465

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		84,600(1)	A	$0	92,303	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.89	01/16/2026		A		126,900		(2)	01/16/2036	Common Stock	126,900	$0	126,900	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

2. The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Acumen Pharmaceuticals (ABOS) disclose in this Form 4 for Amy Schacterle?

The filing shows that Amy Schacterle, Chief Regulatory Officer of Acumen Pharmaceuticals, Inc. (ABOS), received new equity compensation on January 16, 2026, including restricted stock units and stock options tied to the company’s Common Stock.

How many Acumen Pharmaceuticals RSUs were granted to Amy Schacterle and how do they vest?

Amy Schacterle was granted 84,600 restricted stock units (RSUs), each representing one share of Common Stock. The RSUs vest in three equal annual installments starting one year after the grant date, provided she remains in continuous service on each vesting date.

What stock options did Amy Schacterle receive from Acumen Pharmaceuticals and on what terms?

She received an employee stock option for 126,900 shares of Acumen’s Common Stock with an exercise price of $1.89 per share. The option vests in 48 equal monthly installments and becomes fully vested on the fourth anniversary of the grant date, subject to her continuous service.

How many Acumen Pharmaceuticals common shares does Amy Schacterle own after these transactions?

Following the RSU grant, Amy Schacterle is reported as beneficially owning 92,303 shares of Common Stock directly. This figure reflects her holdings after the reported non-derivative transaction.

How many Acumen Pharmaceuticals options does Amy Schacterle hold after the reported grant?

After the derivative transaction, she held 126,900 employee stock options for Acumen Pharmaceuticals Common Stock, as reported in the Form 4.

Were these Acumen Pharmaceuticals equity awards to Amy Schacterle granted for cash consideration?

The Form 4 reports a transaction price of $0 per share for the 84,600 RSUs, indicating they were granted as equity compensation, while the 126,900 options carry an exercise price of $1.89 per share if exercised in the future.